Abstract:Introduction: MRI-guided focused ultrasound (FUS) is an incisionless thermo-ablative procedure that may be used to treat medication-refractory movement disorders, with a growing number of potential anatomic targets and clinical applications. As of this article’s publication, the only US Food and Drug Administration (FDA)-approved uses of FUS for movement disorders are thalamotomy for essential tremor (ET) and tremor-dominant Parkinson’s Disease (PD), and pallidotomy for other cardinal symptoms of PD. We present a state-of-the-art review on all non-FDA approved indications of FUS for movement disorders, beyond the most well-described indications of ET and PD. Our objective was to summarize the safety and efficacy of FUS in this setting and provide a roadmap for future directions of FUS for movement disorders. Methods: A state-of-the-art review was conducted on use of FUS for non-FDA approved movement disorders. All movement disorders excluding FDA-approved uses for ET and PD were included. Results: A total of 25 studies on 172 patients were included. In patients with tremor plus dystonia syndromes ( n = 6), ventralis intermediate nucleus of the thalamus (VIM)-FUS gave >50% tremor reduction, with no improvement in dystonia and worsened dystonia in 2/6 patients. Ventral-oralis complex (VO)-FUS gave >50% improvement for focal hand dystonia ( n = 6) and 100% return to musical performance in musician’s dystonia ( n = 6). In patients with multiple sclerosis (MS) and tremor ( n = 3), improvement in tremor was seen in 2 patients with a favorable skull density ratio; no MS disease change was noted after VIM-FUS. In patients with tremor and comorbid ataxia syndromes ( n = 3), none were found to have worsened ataxia after VIM-FUS; all had clinically significant tremor improvement. Subthalamic nucleus (STN)-FUS for PD ( n = 49) gave approximately 50% improvement in PD motor symptoms, with dystonia and mild dyskinesias as possible adverse effects. Cerebellothalamic tract (CTT-FUS) for ET ( n = 42) gave 55–90% tremor improvement, with gait dysfunction as a rare persistent adverse effect. Pallidothalamic tract (PTT-FUS) for PD ( n = 50) gave approximately 50% improvement in motor symptoms, with mild speech dysfunction as a possible adverse effect. Conclusion: VIM-FUS appeared safe and effective for heterogenous tremor etiologies, and VO-FUS appeared most effective for isolated segmental dystonia. STN-FUS was effective for PD symptom reduction; postoperative dystonia and mild on-medication dyskinesias required medical management. Tractography-based targeting with CTT-FUS for ET and PTT-FUS for PD demonstrated promising early results. Larger prospective trials with long-term follow-up are needed to the evaluate the safety and efficacy non-FDA approved indications for FUS.

The Use of Focused Ultrasound Ablation for Movement Disorders

Focused Ultrasound for Treatment of Movement Disorders: A Review of Non-Food and Drug Administration Approved Indications

The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease

Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease

The emerging role of transcranial magnetic resonance imaging-guided focused ultrasound in functional neurosurgery

Focused ultrasound therapy in movement disorders: management roadmap towards optimal pathway organization

MR-guided focused ultrasound in movement disorders and beyond: Lessons learned and new frontiers

Brain targeting for focused ultrasound essential tremor ablation: proceedings from the 2023 Focused Ultrasound Foundation workshop

Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders

Technical Principles and Clinical Workflow of Transcranial MR-Guided Focused Ultrasound

Focused Ultrasound Thalamotomy for Tremor Treatment Impacts the Cerebello-Thalamo-cortical Network

An experience-based review of HIFU in functional interventional neuroradiology: transcranial MRgFUS thalamotomy for treatment of tremor

Focused ultrasound opening of the blood–brain barrier for treatment of Parkinson's disease

Focused ultrasound in Parkinson's disease: A twofold path toward disease modification

Noninvasive modulation of essential tremor with focused ultrasonic waves

Current and emerging brain applications of MR-guided focused ultrasound

MRI-guided focused ultrasound for essential tremor

Focused ultrasound thalamotomy location determines clinical benefits in patients with essential tremor

Advanced MRI techniques for transcranial high intensity focused ultrasound targeting

Cranial MR-Guided Focused Ultrasound: Clinical Challenges and Future Directions

Device profile of exAblate Neuro 4000, the leading system for brain magnetic resonance guided focused ultrasound technology: an overview of its safety and efficacy in the treatment of medically refractory essential tremor